Phase II study of capecitabine-based concomitant chemoradiation followed by durvalumab as a neoadjuvant strategy in locally advanced rectal cancer: the PANDORA trial
Open Access
- 27 September 2023
- Vol. 8 (5) , 101824
Abstract
No abstract availableKeywords
Funding Information
- AstraZeneca
This publication has 41 references indexed in Scilit:
- No benefit of adjuvant Fluorouracil Leucovorin chemotherapy after neoadjuvant chemoradiotherapy in locally advanced cancer of the rectum (LARC): Long term results of a randomized trial (I-CNR-RT)Radiotherapy and Oncology, 2014
- Chronicle: results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capecitabine plus oxaliplatin (XELOX) versus controlAnnals of Oncology, 2014
- Immunogenic cell death and DAMPs in cancer therapyNature Reviews Cancer, 2012
- Neoadjuvant Treatment Response As an Early Response Indicator for Patients With Rectal CancerJournal of Clinical Oncology, 2012
- Complete Clinical Response After Neoadjuvant Chemoradiation Therapy for Distal Rectal Cancer: Characterization of Clinical and Endoscopic Findings for StandardizationDiseases of the Colon & Rectum, 2010
- Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient dataThe Lancet Oncology, 2010
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Randomized Phase III Study Comparing Preoperative Radiotherapy With Chemoradiotherapy in Nonresectable Rectal CancerJournal of Clinical Oncology, 2008
- Pathological response following long‐course neoadjuvant chemoradiotherapy for locally advanced rectal cancerHistopathology, 2005
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989